J Cancer 2019; 10(19):4442-4454. doi:10.7150/jca.35648 This issue

Review

Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis

Yuqing Wang1, Wenxuan Guo1, XiaoLi Wu2, Ying Zhang3, Ciaran Mannion4, Anatoli Brouchkov5,6, Yan-Gao Man7✉, Tingtao Chen1 ✉

1. Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China
2. JiangXi university of traditional Chinese medicine, College of basic medicine, Nanchang 330000, PR China
3. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
4. Hackensack University Medical Center, Hackensack, NJ, USA
5. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia
6. Tyumen State University, Volodarskogo 6, Tyumen 625003, Russia
7. Department of Pathology, Hackensack Meridian Health-Hackensack University Medical Center, NJ, USA

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang Y, Guo W, Wu X, Zhang Y, Mannion C, Brouchkov A, Man YG, Chen T. Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis. J Cancer 2019; 10(19):4442-4454. doi:10.7150/jca.35648. Available from https://www.jcancer.org/v10p4442.htm

File import instruction

Abstract

As the human microbiota has been confirmed to be of great significance in maintaining health, the dominant bacteria in them have been applied as probiotics to treat various diseases. After the detection of bacteria in tumours, which had previously been considered a sterile region, these bacteria have been isolated and genetically modified for use in tumour therapy. In this review, we sum up the main types of bacteria used in tumour therapy and reveal the mechanisms of both wild type and engineered bacteria in eliminating tumour cells, providing potential possibilities for newly detected, genetically modified, tumour-associated bacteria in anti-tumour therapy.

Keywords: Engineered bacteria, Tumour therapy, Human microbiota, Probiotics